

Other version: http://jac.oxfordjournals.org/cgi/reprint/59/5/1034.pdf
![]() |
No change in calculated creatinine clearance after tenofovir initiation among Thai patients |
|
Authors | ![]() | |
Published in | The journal of antimicrobial chemotherapy. 2007, vol. 59, no. 5, p. 1034-1037 | |
Abstract | OBJECTIVES: Thai patients have a lower average body weight than patients from western Europe or the USA. Tenofovir is largely prescribed at the standard dosage of 300 mg once daily: therefore, the per kilogram dose is higher in Thailand than in the USA. We asked the question whether this higher per kilogram dose was associated with more nephrotoxicity. METHODS: Thai patients from the Staccato trial were treated with tenofovir/lamivudine combined with ritonavir-boosted saquinavir. Creatinine values were measured before the start of tenofovir and then every 12 weeks. Renal function was assessed using the Cockcroft-Gault formula and the MDRD formula. To compare CL(CR) before and after tenofovir, the t-paired or Wilcoxon signed rank tests were used. One-way analysis of variance and Spearman's correlation coefficient were used to study CL(CR) longitudinally. RESULTS: CL(CR) remained stable after a median of 21 weeks on tenofovir (difference of +1.06 mL/min; 95% CI -2.7-4.8, P=0.58), even among patients with underlying diseases. The mean CL(CR) remained stable across time (P=0.17). CONCLUSIONS: We did not find renal dysfunction on tenofovir among Thai patients included in the Staccato trial. Tenofovir could be safely prescribed at a standard dosage of 300 mg once daily in the Thai population. | |
Keywords | Adenine/administration & dosage/adverse effects/ analogs & — Derivatives/therapeutic use — Adult — Antiretroviral Therapy, Highly Active — Antiviral Agents/administration & dosage/ adverse effects — Body Weight — Creatinine/ metabolism — Female — HIV Infections/drug therapy — Humans — Kidney/ drug effects — Kidney Function Tests — Lamivudine/administration & dosage/therapeutic use — Male — Phosphonic Acids/administration & dosage/ adverse effects/therapeutic use — Thailand | |
Identifiers | DOI: 10.1093/jac/dkm064 PMID: 17376791 | |
Full text |
![]() ![]() Other version: http://jac.oxfordjournals.org/cgi/reprint/59/5/1034.pdf |
|
Structures | ||
Research group | Epidémiologie clinique (115) | |
Citation (ISO format) | GAYET-AGERON, Angèle et al. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. In: The journal of antimicrobial chemotherapy, 2007, vol. 59, n° 5, p. 1034-1037. doi: 10.1093/jac/dkm064 https://archive-ouverte.unige.ch/unige:7262 |